In sepsis, CYT107 has an impact on immunometabolism via improving mTOR signaling, GLUT1 surface expression, and glucose uptake by T cells (237) and targeting this metabolism pathway showed promising results in a phase II clinical on patients in septic shock (238). This evidence concerns the gene SLC2A1 and Sepsis.